Biosimilars Conference
October 24 - 25, 2017 - Bethesda, MD US
The Biosimilars Price Competition and Innovation Act (BCPIA) of 2009 created a biosimilars approval pathway in the US with the goal of increasing access to effective biological treatment options while reducing health care costs. At the DIA Biosimilars Conference in 2012, Dr. Janet Woodcock told attendees “biosimilars represent a paradigm shift in the way we make a finding of safety and efficacy.”
This website uses cookies to ensure you get the best experience on our website. Learn more